4 Midcap High Margin and Fast Revenue Growth Stocks to Watch for Future Multibagger Potential: Max Healthcare, Phoenix Mills, Fortis Healthcare and Ajanta Pharma

High margin and fast revenue growth stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Max Healthcare, Phoenix Mills, Fortis Healthcare and Ajanta Pharma meet that test, with market caps from Rs 43,549 crore to Rs 86,889 crore and Max Healthcare offering the largest market cap at Rs 86,889 crore. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and an operating margin of at least 20 per cent and FY26 revenue growth of at least 15 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and an operating margin of at least 20 per cent and FY26 revenue growth of at least 15 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening high margin and fast revenue growth stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 29 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are High Margin and Fast Revenue Growth Stocks and Why Do They Attract Multibagger Interest?

High margin and fast revenue growth stocks are shares of mid sized companies that keep at least twenty paise of operating profit from every rupee of sales while also growing sales by fifteen per cent or more, a rare mix of quality and speed. The four here cover hospitals, retail malls and pharmaceuticals.

Strong margins show pricing power and cost control, and fast revenue growth shows rising demand, so a company with both is building a bigger business without giving up profitability. Within high margin and fast revenue growth stocks, the four companies show rising profit. For high margin and fast revenue growth stocks, both FY26 and the latest quarter showed growth. Whichever way you read high margin and fast revenue growth stocks, the common thread is rising profit backed by complete financial data. With high margin and fast revenue growth stocks, comparing valuation, growth and balance sheet strength together works better than relying on one number. Every company in the table below passed a rising-profit check, and the figures for high margin and fast revenue growth stocks are complete. Read each company’s latest results and exchange filings before acting on high margin and fast revenue growth stocks.

High Margin and Fast Revenue Growth Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 29 October 2026. Ajanta Pharma combines the lowest PE of the group, 38.37, with the highest return on equity, 23.33%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Max Healthcare Institute	851.15	86,889	59.63	60.75	13.42%	0.32	815.00 to 1,221.90
Phoenix Mills	1,969.90	71,341	43.76	31.56	11.14%	0.48	1,465.60 to 2,169.80
Fortis Healthcare	754.90	57,464	53.68	60.75	10.53%	0.35	565.00 to 759.50
Ajanta Pharma	3,459.70	43,549	38.37	36.35	23.33%	0.06	2,380.20 to 3,796.00

Max Healthcare: 24.26% Profit CAGR Since FY22

Max Healthcare Institute runs a network of multi-speciality hospitals in Delhi NCR, Mumbai and other cities. It reported FY26 revenue of Rs 8,536.07 crore, up 18.82% year on year, and net profit of Rs 1,442.41 crore, up 34.07%. Net profit has compounded at 24.26% a year since FY22, while revenue has grown 20.42% a year. Operating margin was 28.15% in FY26. The debt-to-equity ratio is 0.32.

In the June 2026 quarter, revenue rose 16.60% to Rs 2,406.69 crore and net profit grew 4.87% to Rs 322.96 crore. The share price has gained 149.91% over five years. Domestic institutions raised their holding from 17.42% in June 2025 to 29.96% in June 2026. The stock trades at a PE of 59.63 against an industry PE of 60.75, below the sector average, with a return on equity of 13.42%.

Phoenix Mills: 58.28% Profit CAGR Since FY22

Phoenix Mills owns and runs large retail malls across India under the Phoenix Marketcity and Palladium brands, along with offices, hotels and residences. It reported FY26 revenue of Rs 4,593.55 crore, up 15.87% year on year, and net profit of Rs 1,556.61 crore, up 19.60%. Net profit has compounded at 58.28% a year since FY22, while revenue has grown 31.04% a year. Operating margin was 62.83% in FY26. The debt-to-equity ratio is 0.48.

The stock trades at a PE of 43.76 against an industry PE of 31.56. In the June 2026 quarter, revenue rose 13.27% to Rs 1,115.15 crore and net profit grew 23.02% to Rs 393.55 crore. The share price has gained 303.49% over five years and 11.92% over the past year. Domestic institutions raised their holding from 15.47% in September 2025 to 17.31% in September 2026.

Fortis Healthcare: Five-Year Gain of 241.47%

Fortis Healthcare operates a chain of hospitals and diagnostic centres across India. It reported FY26 revenue of Rs 9,178.50 crore, up 16.93% year on year, and net profit of Rs 1,064.19 crore, up 31.48%. Net profit has compounded at 7.73% a year since FY22, while revenue has grown 12.43% a year. Operating margin was 22.41% in FY26. The debt-to-equity ratio is 0.35.

In the June 2026 quarter, revenue rose 17.29% to Rs 2,559.50 crore and net profit grew 2.26% to Rs 272.80 crore. The share price has gained 241.47% over five years. Domestic institutions raised their holding from 29.79% in June 2025 to 32.23% in June 2026. The stock trades at a PE of 53.68 against an industry PE of 60.75, below the sector average.

Ajanta Pharma: Return on Equity of 23.33%

Ajanta Pharma sells branded generics in ophthalmology, dermatology, cardiology and pain management in India, Africa and Asia. It reported FY26 revenue of Rs 5,624.93 crore, up 18.60% year on year, and net profit of Rs 1,056 crore, up 14.73%. Net profit has compounded at 10.33% a year since FY22, while revenue has grown 12.94% a year. Operating margin was 28.74% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

The stock trades at a PE of 38.37 against an industry PE of 36.35, with a return on equity of 23.33%. In the June 2026 quarter, revenue rose 27.68% to Rs 1,696.86 crore and net profit grew 30.89% to Rs 334.22 crore. The share price has gained 125.31% over five years and 35.42% over the past year. Domestic institutions raised their holding from 17.90% in September 2025 to 21.94% in September 2026.

High Margin and Fast Revenue Growth Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these high margin and fast revenue growth stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	4-Year Net Profit CAGR	Operating Margin (Latest Quarter)
Max Healthcare	8,536.07	1,442.41	18.82%	20.42%	24.26%	27.00%
Phoenix Mills	4,593.55	1,556.61	15.87%	31.04%	58.28%	63.42%
Fortis Healthcare	9,178.50	1,064.19	16.93%	12.43%	7.73%	22.22%
Ajanta Pharma	5,624.93	1,056	18.60%	12.94%	10.33%	30.41%

Check the Univest Screener for live data on these high margin and fast revenue growth stocks

Institutional Holding in Max Healthcare, Phoenix Mills, Fortis Healthcare and Ajanta Pharma

Institutional holding shows who is backing these high margin and fast revenue growth stocks alongside the promoter. The table uses the latest reported quarter for each. Max Healthcare has the deepest institutional backing, with FII and DII together holding 71.74% as of June 2026. Domestic institutions increased their holding over the past year in Max Healthcare (from 17.42% to 29.96%), Phoenix Mills (from 15.47% to 17.31%), Fortis Healthcare (from 29.79% to 32.23%) and Ajanta Pharma (from 17.90% to 21.94%).

Stock	Promoter	FII	DII	Public	Quarter
Max Healthcare	23.71%	41.78%	29.96%	4.56%	June 2026
Phoenix Mills	47.24%	31.62%	17.31%	3.83%	September 2026
Fortis Healthcare	31.17%	25.20%	32.23%	11.40%	June 2026
Ajanta Pharma	63.47%	7.63%	21.94%	6.96%	September 2026

Risks to Weigh in High Margin and Fast Revenue Growth Stocks

Being careful with high margin and fast revenue growth stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Phoenix Mills trades at a PE of 43.76 against an industry PE of 31.56, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between High Margin and Fast Revenue Growth Stocks

Picking from high margin and fast revenue growth stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (31.56 to 60.75) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Max Healthcare, Phoenix Mills, Fortis Healthcare and Ajanta Pharma live prices.

Conclusion

Among high margin and fast revenue growth stocks, Max Healthcare stands out for the largest market cap at Rs 86,889 crore, Phoenix Mills for the fastest profit growth, 58.28% a year since FY22, Fortis Healthcare for 16.93% revenue growth in FY26 and Ajanta Pharma for the highest return on equity at 23.33%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing high margin and fast revenue growth stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on High Margin and Fast Revenue Growth Stocks to Watch

Which are the best high margin and fast revenue growth stocks to watch for multibagger potential?

Ans. Max Healthcare, Phoenix Mills, Fortis Healthcare and Ajanta Pharma are the 4 names this list highlights, with market caps of Rs 86,889 crore, Rs 71,341 crore, Rs 57,464 crore and Rs 43,549 crore respectively. Max Healthcare is notable for the largest market cap at Rs 86,889 crore. Phoenix Mills stands out for the fastest profit growth, 58.28% a year since FY22. Fortis Healthcare offers 16.93% revenue growth in FY26. Ajanta Pharma brings the highest return on equity at 23.33%. These are watchlist names for high margin and fast revenue growth stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Ajanta Pharma a good stock for long-term investors?

Ans. Ajanta Pharma has a return on equity of 23.33%, a PE of 38.37 against an industry PE of 36.35 and a market cap of Rs 43,549 crore. Net profit has compounded at 10.33% a year since FY22, and FY26 revenue rose 18.60% while June 2026 quarter net profit grew 30.89%. Long-term returns in high margin and fast revenue growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Phoenix Mills become a multibagger from here?

Ans. Phoenix Mills has already gained 303.49% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in high margin and fast revenue growth stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 58.28% a year since FY22, and FY26 revenue rose 15.87%. At a PE of 43.76 against an industry PE of 31.56, valuation should be checked against that growth before investing.

What is the market cap of Max Healthcare, Phoenix Mills, Fortis Healthcare and Ajanta Pharma?

Ans. As of 29 October 2026, Max Healthcare has a market cap of Rs 86,889 crore, Phoenix Mills has a market cap of Rs 71,341 crore, Fortis Healthcare has a market cap of Rs 57,464 crore and Ajanta Pharma has a market cap of Rs 43,549 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on high margin and fast revenue growth stocks.

What are the risks of investing in high margin and fast revenue growth stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Phoenix Mills trades at a PE of 43.76 against an industry PE of 31.56, so earnings growth needs to hold up.

Why is Phoenix Mills trading at a PE of 43.76?

Ans. Phoenix Mills’ PE of 43.76 compares with an industry PE of 31.56. The market is paying a premium for profit growth of 58.28% a year since FY22, latest-quarter profit growth of 23.02% and FY26 revenue growth of 15.87%, which also means the stock is more sensitive if growth slows. Investors in high margin and fast revenue growth stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Max Healthcare, Phoenix Mills, Fortis Healthcare and Ajanta Pharma?

Ans. As of the latest reported quarter, FII and DII together hold 71.74% of Max Healthcare (41.78% and 29.96%), 48.93% of Phoenix Mills (31.62% and 17.31%), 57.43% of Fortis Healthcare (25.20% and 32.23%) and 29.57% of Ajanta Pharma (7.63% and 21.94%). Rising institutional holding is a useful signal in high margin and fast revenue growth stocks, though it should be read with earnings trends rather than on its own.